Dr. Daniel Petrylak on Early Trials for Urothelial Bladder Cancer Treatment
Daniel P. Petrylak, MD, talks about taking the clinical trials examining MPDL3280A a step further for bladder cancer patients.
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, professor and co-director, Signal Transduction Research Program, Yale Cancer Center, talks about taking the clinical trials examining MPDL3280A (antiPD-L1) a step further.
Petrylak says patients with a high level of PD-L1 expression who are treated with the drug often have better responses than those without. Moreover, while MPDL3280A is still in its infancy, the treatment could be evolved into something that may be able to help a wider range of patients in the future, he adds.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
